ARTICLE | Clinical News
Isis Phase II ulcerative colitis results
October 10, 2001 7:00 AM UTC
ISIP said its ISIS 2302 antisense inhibitor of ICAM-1 improved symptoms of active distal ulcerative colitis (UC) in a European placebo-controlled, dose-escalation Phase II trial of 40 patients. Patien...